---
confidence_score: 0.9
created: '2026-02-14T12:00:00+00:00'
description: A group of specialized biomarkers including NGAL, KIM-1, Cystatin C,
  TIMP-2, and IGFBP7 used for the early detection, risk stratification, and monitoring
  of acute kidney injury (AKI). These markers detect tubular damage 24-48 hours before
  serum creatinine rises, enabling earlier clinical intervention and improved outcomes.
dg-home: false
dg-publish: true
evidence_level: 5
gardenUsername: stucktest
id: acute_kidney_injury_markers
last_modified: 2026-06-21T00:00:00+0000
permalink: /garden/stucktest/biomarker/acute-kidney-injury-markers/
provenance: curated
slug: acute-kidney-injury-markers
source: Manual
tags:
- biomarker
- nephrology
- kidney_health
- diagnostics
- critical_care
- aki
templateEngineOverride: njk
title: Acute Kidney Injury Markers
type: biomarker
updated: 2026-06-21T00:00:00+0000
---

{% raw %}
<h1>Acute Kidney Injury Markers</h1>
<h2>Overview</h2>
<p>Acute kidney injury (AKI) markers are a group of specialized biomarkers that detect renal tubular damage earlier and more specifically than traditional markers like serum creatinine and BUN. The key markers include neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1), cystatin C, and the cell-cycle arrest markers tissue inhibitor of metalloproteinases-2 (TIMP-2) and insulin-like growth factor binding protein 7 (IGFBP7).</p>
<p>Serum creatinine, the traditional AKI marker, has significant limitations: it only rises 24-48 hours after actual kidney damage occurs, is influenced by muscle mass, hydration status, and medications, and cannot distinguish between pre-renal, intrinsic, and post-renal causes of kidney dysfunction. The newer AKI biomarkers address these gaps by directly reflecting tubular cell injury rather than simply reduced glomerular filtration.</p>
<p>The FDA-cleared NephroCheck test (measuring [TIMP-2]x[IGFBP7]) and urine NGAL assays have become the most widely adopted tests in clinical practice, particularly for predicting AKI risk in critically ill patients, post-cardiac surgery, and after contrast-enhanced imaging procedures.</p>
<h2>Reference Ranges</h2>
<h3>NGAL (Neutrophil Gelatinase-Associated Lipocalin)</h3>
<table>
<thead>
<tr>
<th>Range</th>
<th>Value</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 150 ng/mL (urine)</td>
<td>No tubular injury</td>
</tr>
<tr>
<td>Elevated</td>
<td>150 - 500 ng/mL</td>
<td>Early tubular injury; AKI risk</td>
</tr>
<tr>
<td>High</td>
<td>&gt; 500 ng/mL</td>
<td>Significant AKI; monitor closely</td>
</tr>
</tbody>
</table>
<h3>KIM-1 (Kidney Injury Molecule-1)</h3>
<table>
<thead>
<tr>
<th>Range</th>
<th>Value</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 1.0 ng/mL (urine)</td>
<td>No proximal tubule injury</td>
</tr>
<tr>
<td>Elevated</td>
<td>&gt; 1.0 ng/mL</td>
<td>Proximal tubule damage present</td>
</tr>
</tbody>
</table>
<h3>NephroCheck ([TIMP-2] x [IGFBP7])</h3>
<table>
<thead>
<tr>
<th>Range</th>
<th>Value</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk</td>
<td>&lt; 0.3</td>
<td>AKI unlikely within 12 hours</td>
</tr>
<tr>
<td>Moderate Risk</td>
<td>0.3 - 2.0</td>
<td>Consider nephrology consult and monitoring</td>
</tr>
<tr>
<td>High Risk</td>
<td>&gt; 2.0</td>
<td>AKI likely within 12 hours; aggressive management warranted</td>
</tr>
</tbody>
</table>
<h3>Cystatin C (GFR-based)</h3>
<table>
<thead>
<tr>
<th>Range</th>
<th>Value</th>
<th>Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>0.6 - 1.1 mg/L (serum)</td>
<td>Normal GFR</td>
</tr>
<tr>
<td>Elevated</td>
<td>&gt; 1.1 mg/L</td>
<td>Reduced GFR; may indicate AKI or CKD</td>
</tr>
</tbody>
</table>
<p><strong>Notes:</strong></p>
<ul>
<li>NGAL can be measured in both urine and plasma; urine NGAL is more specific for kidney injury</li>
<li>KIM-1 is specific to proximal tubule injury and appears in urine only after brush border damage</li>
<li>NephroCheck is FDA-cleared for AKI risk stratification in critically ill patients (KDIGO stage 2-3 prediction)</li>
<li>Cystatin C reflects GFR rather than tubular injury; rises earlier than creatinine in AKI</li>
</ul>
<h2>Testing Information</h2>
<table>
<thead>
<tr>
<th>Parameter</th>
<th>Detail</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Measurement Unit</strong></td>
<td>Varies by marker (NGAL: ng/mL, KIM-1: pg/mL or ng/mL, TIMP-2xIGFBP7: (ng/mL)^2/1000)</td>
</tr>
<tr>
<td><strong>Sample Type</strong></td>
<td>Urine (NGAL, KIM-1, TIMP-2xIGFBP7) and Blood (NGAL, Cystatin C)</td>
</tr>
<tr>
<td><strong>Fasting Required</strong></td>
<td>No</td>
</tr>
<tr>
<td><strong>Preferred Method</strong></td>
<td>ELISA or immunoturbidimetric for NGAL/KIM-1; automated immunoassay for NephroCheck</td>
</tr>
<tr>
<td><strong>Test Frequency</strong></td>
<td>Serial measurement every 6-12 hours in ICU/high-risk settings; baseline + 24h post-procedure for contrast nephropathy screening</td>
</tr>
</tbody>
</table>
<h2>Factors Affecting Levels</h2>
<p><strong>Increase AKI Markers:</strong></p>
<ul>
<li>Nephrotoxic medications (aminoglycosides, cisplatin, amphotericin B, NSAIDs, ACE inhibitors in renal artery stenosis)</li>
<li>Iodinated contrast media (contrast-induced nephropathy)</li>
<li>Sepsis and systemic inflammatory response syndrome (SIRS)</li>
<li>Cardiac surgery (especially with cardiopulmonary bypass)</li>
<li>Major trauma and rhabdomyolysis (myoglobin nephrotoxicity)</li>
<li>Urinary tract obstruction (post-renal AKI)</li>
<li>Severe heart failure (cardiorenal syndrome)</li>
<li>Hepatorenal syndrome</li>
<li>Volume depletion and hypotension (pre-renal AKI progressing to intrinsic)</li>
</ul>
<p><strong>Decrease AKI Markers:</strong></p>
<ul>
<li>Adequate hydration and renal perfusion</li>
<li>Avoidance of nephrotoxic agents</li>
<li>Timely treatment of sepsis and infection</li>
<li>NAC supplementation (evidence for contrast-induced nephropathy prevention)</li>
<li>Optimal glycemic control in diabetic patients</li>
</ul>
<h2>Clinical Significance</h2>
<p><strong>Elevated AKI markers indicate:</strong></p>
<ul>
<li><strong>Early tubular injury</strong> -- NGAL and KIM-1 rise within 2-6 hours of tubular damage, enabling diagnosis 24-48 hours before creatinine increases</li>
<li><strong>AKI risk stratification</strong> -- NephroCheck [TIMP-2]x[IGFBP7] &gt;2.0 predicts KDIGO stage 2-3 AKI within 12 hours with high sensitivity</li>
<li><strong>Contrast-induced nephropathy</strong> -- Urine NGAL at 4-6 hours post-contrast predicts CI-AKI with AUC &gt;0.90</li>
<li><strong>Sepsis-associated AKI</strong> -- NGAL distinguishes septic AKI from transient creatinine elevation due to hemodynamic changes</li>
<li><strong>Cardiac surgery AKI</strong> -- Post-operative NGAL and NephroCheck identify patients at risk for AKI requiring renal replacement therapy</li>
<li><strong>Drug nephrotoxicity monitoring</strong> -- KIM-1 is specific for proximal tubule damage from aminoglycosides, cisplatin, and other nephrotoxins</li>
</ul>
<p><strong>Clinical utility over creatinine:</strong></p>
<ul>
<li>Earlier detection (2-6 hours vs 24-48 hours)</li>
<li>Tissue-specific (tubular injury vs functional GFR change)</li>
<li>Less influenced by muscle mass, age, sex, diet</li>
<li>Can distinguish AKI subtypes (pre-renal vs intrinsic)</li>
</ul>
<p><strong>Monitoring use cases:</strong></p>
<ul>
<li>ICU admission AKI screening</li>
<li>Post-cardiac surgery and major procedure monitoring</li>
<li>Contrast-enhanced imaging follow-up</li>
<li>Nephrotoxic drug therapy monitoring</li>
<li>Kidney transplant rejection surveillance</li>
</ul>
<h2>Strategies to Improve</h2>
<ol>
<li><strong>Optimize hemodynamics</strong> -- Maintain adequate MAP (&gt;65 mmHg) and renal perfusion pressure; treat hypovolemia with balanced crystalloids</li>
<li><strong>Avoid nephrotoxins</strong> -- Review medication list for NSAIDs, aminoglycosides, IV contrast; use lowest necessary doses of nephrotoxic drugs</li>
<li><strong>NAC for contrast procedures</strong> -- 600-1200 mg oral NAC twice daily on day before and day of contrast-enhanced procedure (evidence level 2, primarily for high-risk patients)</li>
<li><strong>Adequate hydration</strong> -- Isotonic saline or sodium bicarbonate infusion before and after contrast administration in high-risk patients</li>
<li><strong>Glycemic control</strong> -- Maintain blood glucose 140-180 mg/dL in critically ill patients; avoid both hyperglycemia and hypoglycemia</li>
<li><strong>Timely source control</strong> -- Early antibiotic therapy and source identification in sepsis reduces AKI progression</li>
</ol>
<h2>Relationships</h2>
<h3>Associated With Condition</h3>
<p>ASSOCIATED_WITH_CONDITION::<a href="/garden/stucktest/condition/acute-kidney-injury/" class="internal-link">Acute Kidney Injury</a><br />
ASSOCIATED_WITH_CONDITION::<a href="/garden/stucktest/condition/chronic-kidney-disease/" class="internal-link">Chronic Kidney Disease</a><br />
ASSOCIATED_WITH_CONDITION::<a href="/garden/stucktest/condition/sepsis/" class="internal-link">Sepsis</a><br />
ASSOCIATED_WITH_CONDITION::<a href="/garden/stucktest/condition/heart-failure/" class="internal-link">Heart Failure</a></p>
<h3>Indicates Organ Health</h3>
<p>INDICATES_ORGAN_HEALTH::<a href="/garden/stucktest/organ/kidneys/" class="internal-link">Kidneys</a> (direct markers of renal tubular integrity and function, Evidence Level 1a)</p>
<h3>Predicts Risk</h3>
<p>PREDICTS_RISK::<a href="/garden/stucktest/condition/acute-kidney-injury/" class="internal-link">Acute Kidney Injury</a><br />
PREDICTS_RISK::<a href="/garden/stucktest/condition/chronic-kidney-disease/" class="internal-link">Chronic Kidney Disease</a></p>
<h3>Correlated With</h3>
<p>CORRELATED_WITH::<a href="/garden/stucktest/labtest/cystatin-c/" class="internal-link">Cystatin C</a><br />
CORRELATED_WITH::<a href="/garden/stucktest/labtest/creatinine/" class="internal-link">Creatinine</a><br />
CORRELATED_WITH::<a href="/garden/stucktest/labtest/blood-urea-nitrogen/" class="internal-link">Blood Urea Nitrogen</a></p>
<h3>Affected By Supplement</h3>
<p>AFFECTED_BY_SUPPLEMENT::<a href="/garden/stucktest/supplement/nac/" class="internal-link">NAC</a><br />
AFFECTED_BY_SUPPLEMENT::<a href="/garden/stucktest/supplement/coenzyme-q10/" class="internal-link">Coenzyme Q10</a></p>
<h2>References</h2>
<ul>
<li>Kashani K et al. <em>N Engl J Med.</em> 2013;369(22):2116-2125 -- Discovery and validation of cell-cycle arrest biomarkers for AKI prediction (PMID: 24206459)</li>
<li>Makris K, Spanou L. <em>Clin Chem Lab Med.</em> 2016;54(8):1291-1307 -- Acute kidney injury biomarkers (PMID: 26932286)</li>
<li>Haase M et al. <em>J Am Coll Cardiol.</em> 2009;54(21):1964-1971 -- NGAL for early detection of AKI after cardiac surgery (PMID: 19892242)</li>
<li>Vaidya VS et al. <em>Am J Physiol Renal Physiol.</em> 2006;290(3):F517-529 -- KIM-1 as a biomarker of renal injury (PMID: 16303851)</li>
<li>Tujios SR, Vaidya VS. <em>Kidney Int.</em> 2016;90(4):702-707 -- AKI biomarkers in clinical practice (PMID: 27428513)</li>
<li>Bagshaw SM et al. <em>Crit Care.</em> 2010;14(4):R160 -- Systematic review of NGAL for AKI diagnosis (PMID: 20670428)</li>
</ul>

{% endraw %}